(3,3-dimethylbutanoyl)glycine | 883802-93-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3,3-dimethylbutanoyl)glycine
• 英文别名: 2-(3,3-dimethylbutanamido)acetic acid；2-(3,3-dimethylbutanoylamino)acetic acid
• CAS: 883802-93-5
• 化学式: C₈H₁₅NO₃
• mdl: MFCD01313936
• 分子量: 173.212
• InChiKey: CKPFPZCUQJFSPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (S)-2-((3-((4-(dimethylamino)phenyl)carbamoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)acetate 、 (3,3-dimethylbutanoyl)glycine 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 羟胺钾盐 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 (S)-N-(4-(dimethylamino)phenyl)-2-((3,3-dimethylbutanoyl)glycyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
  参考文献：
  名称：

  Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability

  摘要：

  Histone deacetylase inhibitors with desirable pharmacokinetic profiles which can be delivered to solid tumor tissues in large amount might be promising to treat solid tumor effectively. Herein, structural modification of a previously reported tetrahydroisoquinoline-based HDAC inhibitor 1 was carried out to improve its plasma stability for more feasible drug delivery. Among three newly synthesized analogs, the in vitro rat plasma stability of compound 2 (t(1/2) = 630 min) was over 5-fold improved than its parent 1 (t(1/2) = 103 min). In vitro activity evaluation showed that compound 2 and 1 exhibited similar HDACs inhibitory activity, which was validated by western blot analysis and antiproliferative assay. Moreover, compared with 1, compound 2 exhibited comparable, if not higher, in vivo antitumor activity in a human breast carcinoma (MDA-MB-231) xenograft model. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.06.039
• 作为产物：
  描述：

  3,3-二甲基丁酰氯 、 聚甘氨酸 在 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以40%的产率得到(3,3-dimethylbutanoyl)glycine
  参考文献：
  名称：

  [EN] SMALL MOLECULE ANTAGONISTS OF PF4
  [FR] ANTAGONISTES À PETITES MOLÉCULES DE PF4

  摘要：

  本申请提供了式（I）的化合物或其药学上可接受的盐，其中Y，R1，R2，R3和R4如本文所述。还公开了使用这些化合物抑制PF4四聚体化和治疗相关疾病和状况的方法，例如肝素诱导的血小板减少和血栓形成（HITT）和疫苗诱导的免疫性血栓性血小板减少症（VITT），制备这些化合物的方法以及含有这些化合物的制药组合物。

  公开号：

  WO2022073003A1

文献信息

• Rigidified Compounds for Modulating Heparanase Activity
  申请人：Gelder M. Van Joel

  公开号：US20080039456A1

  公开（公告）日：2008-02-14

  Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.

  揭示了一种新颖的刚性化合物，其具有类似罗丹啉的残基和至少一个连接到类似罗丹啉残基的芳基或杂芳基残基，其中这些化合物的核心结构，如规范中定义的那样，其特征是具有一个或零个可自由旋转的键。还披露了含有这些刚性化合物的药物组合物以及用于调节肝素酶活性的用途，从而治疗与肝素酶相关的疾病和紊乱，并用于调节肝素结合蛋白的活性以及治疗与肝素结合蛋白相关的疾病和紊乱，以及治疗至少部分可通过罗丹啉或罗丹啉类似物治疗的医疗状况的用途。
• A General Amino Acid Synthesis Enabled by Innate Radical Cross-Coupling
  作者：Shengyang Ni、Alberto F. Garrido-Castro、Rohan R. Merchant、Justine N. de Gruyter、Daniel C. Schmitt、James J. Mousseau、Gary M. Gallego、Shouliang Yang、Michael R. Collins、Jennifer X. Qiao、Kap-Sun Yeung、David R. Langley、Michael A. Poss、Paul M. Scola、Tian Qin、Phil S. Baran

  DOI：10.1002/anie.201809310

  日期：2018.10.26

  The direct union of primary, secondary, and tertiary carboxylic acids with a chiral glyoxylate‐derived sulfinimine provides rapid access into a variety of enantiomerically pure α‐amino acids (>85 examples). Characterized by operational simplicity, this radical‐based reaction enables the modular assembly of exotic α‐amino acids, including both unprecedented structures and those of established industrial

  伯、仲和叔羧酸与手性乙醛酸衍生的亚磺胺的直接结合可以快速获得各种对映体纯的 α-氨基酸（> 85 个例子）。这种基于自由基的反应以操作简单为特点，能够实现外来α-氨基酸的模块化组装，包括前所未有的结构和已确定的工业价值的结构。所描述的方法在高通量库合成中表现良好，并且已经在三个不同的药物化学活动中实施。
• Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators
  申请人：Edmondson Scott

  公开号：US20100113492A1

  公开（公告）日：2010-05-06

  Certain novel substituted aminopyrimidines are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

  某些新型取代氨基嘧啶是人体胆囊收缩素受体的配体，特别是人体胆囊收缩素-1受体（CCK-1R）的选择性配体。因此，它们对于治疗、控制或预防对CCK-1R调节敏感的疾病和疾病是有用的，例如肥胖症和糖尿病。
• RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY
  申请人：InSight Biopharmaceuticals Ltd.

  公开号：EP1846383A2

  公开（公告）日：2007-10-24
• COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY
  申请人：Graybug Vision, Inc.

  公开号：US20210214374A1

  公开（公告）日：2021-07-15

  The present invention provides new prodrugs of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.